NuScale Is Already Down 70%. Here's the Price I'd Actually Start Buying.

NuScale Power shares have fallen roughly 70% over the past year to about $9.70, yet the article argues the valuation remains difficult to justify given Q2 revenue of only about $75,000 and no binding commercial order. The company held approximately $1.9 billion of cash, equivalents and investments at June-end, but raised roughly $985 million through the sale of 89.7 million shares in H1 2026, creating significant dilution. A potential TVA deployment of up to 6GW remains non-binding; the author would consider a small position near $7 per share, or above that level only if a definitive TVA agreement is signed.

Analysis

SMR’s equity is effectively a long-dated call option on converting regulatory readiness into financeable contracted backlog, not a near-term nuclear-power earnings story. The relevant valuation anchor is enterprise value after cash, but that cushion should be discounted by ongoing corporate burn, project-development spend, and the probability that customer commitments require further equity issuance before project financing is available. The recent issuance demonstrates that a higher share price can reduce financing risk for the company while transferring substantial dilution risk to holders.

The key gating event is not a memorandum, supply-chain roster, or design approval; it is a binding, creditworthy offtake arrangement with defined pricing, construction responsibility, and escalation terms. Even after such an agreement, site-specific licensing, interconnection, HALEU/fuel availability, EPC cost guarantees, and utility cost recovery can delay monetization by years. This creates an asymmetric near-term setup: absent a definitive contract within 1-3 months, speculative capital can continue to rotate out; a credible contract could re-rate the stock sharply before its economics are fully underwritten.

Competitive dynamics favor nuclear suppliers with existing manufacturing and defense/utility customer bases over pure-play developers during the pre-revenue phase. BWXT is a cleaner "picks-and-shovels" exposure to advanced-reactor procurement and nuclear-services spending, while SMR carries concentrated design, commercialization, and dilution risk. Contrarian point: a move toward $7 is not automatically a value signal; if it results from another equity raise or a delayed TVA decision, the lower price may simply reflect a reduced per-share claim on the same uncertain asset base.

A bullish SMR thesis is falsified by another material share issuance before binding offtake, a TVA/ENTRA1 timeline slip, or project economics that require subsidies or power prices materially above regional market benchmarks. Conversely, disclosed contracted capacity, customer deposits, fixed-price EPC commitments, and a funded fuel plan would justify reassessing the valuation framework even above the suggested entry level.

Key Decisions for Investors

• Do not initiate a core SMR long at current levels solely on cash backing or technical certification; set an event-driven alert for a binding TVA/ENTRA1 offtake agreement with pricing, capacity, and financing terms. Re-underwrite within 24 hours of disclosure rather than chasing an initial headline move.
• For high-risk tactical exposure, stage a small SMR position only near $7, with maximum initial sizing of 25-33% of intended exposure; add only after confirmation that no incremental ATM issuance accompanied the decline. Risk is a break below $6 on dilution or project slippage; upside requires a contracted-backlog catalyst over 3-12 months.
• Prefer long BWXT versus SMR as a 6-18 month pair trade for nuclear-capex exposure: BWXT offers lower commercialization risk and should benefit from broader reactor and defense-nuclear activity even if NuScale’s specific deployment does not proceed. Exit the relative thesis if SMR secures fully financed, fixed-price commercial orders that materially de-risk its first deployment.
• Avoid shorting SMR outright ahead of contract or policy headlines; its high retail/nuclear-theme sensitivity makes gap risk substantial. If options liquidity and implied volatility are acceptable, use defined-risk put spreads rather than an uncovered short to express a 1-3 month no-contract/dilution scenario.